CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries

Original Research2020 Jul 18.

JOURNAL:ESC Heart Fail. Article Link

Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study

JA Borovac, D Glavas, ZS Grabovac et al. Keywords: acute decompensated heart failure; catestatin; HF; hospital mortality; risk stratification; soluble suppression of tumourigenicity

Full Text PDF